Can glypican-3 be a disease-specific biomarker?
Abstract Background Glypican-3 (GPC3) is a cell surface-bound proteoglycan which has been identified as a potential biomarker candidate in hepatocellular carcinoma, lung carcinoma, severe pneumonia, and acute respiratory distress syndrome (ARDS). The aim of our review is to evaluate whether GPC3 has...
Main Authors: | Chaolei Chen, Xiaomin Huang, Zhaojian Ying, Dengmin Wu, Yani Yu, Xiangdong Wang, Chengshui Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-05-01
|
Series: | Clinical and Translational Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40169-017-0146-5 |
Similar Items
-
MAY GLYPICAN-3 BE A NOVEL BIOMARKER AND POTENTIAL THERAPEUTIC TARGET IN HEPATOCELLULAR CANCER?
by: Irina I. Ivanova
Published: (2018-03-01) -
The Expression, Regulation, and Biomarker Potential of Glypican-1 in Cancer
by: Sen Wang, et al.
Published: (2019-07-01) -
Glypican-3 Expression in Breast Cancer
by: Ching-Hua Tsai, et al.
Published: (2015-12-01) -
Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma
by: Meghan M. Bell, et al.
Published: (2021-12-01) -
Glypican-3 Stimulates the WNT Signaling Pathway by Facilitating/Stabilizing the Interaction of WNT LIigand and Frizzled Receptor
by: Martin, Tonya
Published: (2010)